Toward Ameliorating Insulin Resistance: Targeting a Novel PAK1 Signaling Pathway Required for Skeletal Muscle Mitochondrial Function

The p21-activated kinase 1 (PAK1) is required for insulin-stimulated glucose uptake in skeletal muscle cells. However, whether PAK1 regulates skeletal muscle mitochondrial function, which is a central determinant of insulin sensitivity, is unknown. Here, the effect of modulating PAK1 levels (knockdo...

Full description

Saved in:
Bibliographic Details
Main Authors: Rekha Balakrishnan (Author), Pablo A. Garcia (Author), Rajakrishnan Veluthakal (Author), Janice M. Huss (Author), Joseph M. Hoolachan (Author), Debbie C. Thurmond (Author)
Format: Book
Published: MDPI AG, 2023-08-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_fa5f47e8f89f4b80a08ae9cc988484c8
042 |a dc 
100 1 0 |a Rekha Balakrishnan  |e author 
700 1 0 |a Pablo A. Garcia  |e author 
700 1 0 |a Rajakrishnan Veluthakal  |e author 
700 1 0 |a Janice M. Huss  |e author 
700 1 0 |a Joseph M. Hoolachan  |e author 
700 1 0 |a Debbie C. Thurmond  |e author 
245 0 0 |a Toward Ameliorating Insulin Resistance: Targeting a Novel PAK1 Signaling Pathway Required for Skeletal Muscle Mitochondrial Function 
260 |b MDPI AG,   |c 2023-08-01T00:00:00Z. 
500 |a 10.3390/antiox12091658 
500 |a 2076-3921 
520 |a The p21-activated kinase 1 (PAK1) is required for insulin-stimulated glucose uptake in skeletal muscle cells. However, whether PAK1 regulates skeletal muscle mitochondrial function, which is a central determinant of insulin sensitivity, is unknown. Here, the effect of modulating PAK1 levels (knockdown via siRNA, overexpression via adenoviral transduction, and/or inhibition of activation via IPA3) on mitochondrial function was assessed in normal and/or insulin-resistant <i>rat</i> L6.GLUT4myc and <i>human</i> muscle (LHCN-M2) myotubes. <i>Human</i> type 2 diabetes (T2D) and non-diabetic (ND) skeletal muscle samples were also used for validation of the identified signaling elements. PAK1 depletion in myotubes decreased mitochondrial copy number, respiration, altered mitochondrial structure, downregulated PGC1α (a core regulator of mitochondrial biogenesis and oxidative metabolism) and <i>PGC1α</i> activators, p38 mitogen-activated protein kinase (p38MAPK) and activating transcription factor 2 (ATF2). PAK1 enrichment in insulin-resistant myotubes improved mitochondrial function and rescued <i>PGC1α</i> expression levels. Activated PAK1 was localized to the cytoplasm, and PAK1 enrichment concurrent with p38MAPK inhibition did not increase <i>PGC1α</i> levels. PAK1 inhibition and enrichment also modified nuclear phosphorylated-ATF2 levels. T2D <i>human</i> samples showed a deficit for <i>PGC1α</i>, and PAK1 depletion in LHCN-M2 cells led to reduced mitochondrial respiration. Overall, the results suggest that PAK1 regulates muscle mitochondrial function upstream of the p38MAPK/ATF2/<i>PGC1α</i>-axis pathway. 
546 |a EN 
690 |a type 2 diabetes 
690 |a insulin resistance 
690 |a skeletal muscle 
690 |a mitochondria 
690 |a PAK1 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Antioxidants, Vol 12, Iss 9, p 1658 (2023) 
787 0 |n https://www.mdpi.com/2076-3921/12/9/1658 
787 0 |n https://doaj.org/toc/2076-3921 
856 4 1 |u https://doaj.org/article/fa5f47e8f89f4b80a08ae9cc988484c8  |z Connect to this object online.